XOMA (XOMA +7.1%) says its partner, Servier has begun phase 3 clinical trials of of Gevokizumab...

|About: XOMA Corporation (XOMA)|By:, SA News Editor

XOMA (XOMA +7.1%) says its partner, Servier has begun phase 3 clinical trials of of Gevokizumab in several European countries. The study is intended to test the efficacy and safety of the drug in the treatment of patients with Behçet's Disease uveitis.